Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Immunovant, Inc.NASDAQ: IMVT
Net Income · Q2 FY2027 · quarter ended Sep 2026
Net income dips below year-ago levels
Q2 FY2027 net income of $97.25M (cash outflow) fell 23.1% year over year, behind the +9.5% change in trailing-twelve-month net income. Sequentially, it fell 36.5% from the prior quarter. Over 3 fiscal years it compounded at +33.8% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2026 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$551.88M (+9.2%) for the fiscal year ending Mar 2027, a slowdown from the +22.2% reported in FY2026.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$97.25M-36.5% QoQ
- Last fiscal yearMar 2026
- -$505.61M+22.2% YoY
- LTMSep 2026
- -$508.96M+9.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -23.1% | +20.6% | +43.7 pp |
| 1 year | +22.2% | +9.2% | -13.0 pp |
| 3-year CAGR | +33.8% | -55.3% | -89.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2026
- (505.61M) USD
- Year-over-year change
- -22.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (505.61M) | -22.2% |
| FY2025 | 2025-03-31 | (413.84M) | -59.6% |
| FY2024 | 2024-03-31 | (259.34M) | -22.9% |
| FY2023 | 2023-03-31 | (210.96M) | -34.6% |
| FY2022 | 2022-03-31 | (156.73M) | — |
Net Income vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 net income of $508.96M is the largest of the 11 companies compared; the peer median is $135.19M.
- Its year-over-year change of +9.5% is the 6th highest of 11, against a peer median of +12.8%.
- Net income amounts to 7173.5% of revenue for IMVT, versus a peer median of 36.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $508.96M | +9.5% | +33.8% | 7173.5% | |
| LTM Mar 2026 | $425.15M | +161.2% | +46.8% | — | |
| LTM Mar 2026 | $221.04M | +23.7% | — | — | |
| LTM Mar 2026 | $196.48M | +17.4% | +13.3% | — | |
| LTM Mar 2026 | $175.43M | +38.4% | +46.9% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $166.09M | +1.5% | — | — |
| LTM Sep 2026 | $106.06M | -76.3% | — | 11.8% | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Mar 2026 | $26.79M | -81.0% | — | 11.5% | |
| Peer median (excluding IMVT) | $135.19M | +12.8% | +13.3% | 36.8% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 34.24M | 32.3M | 41.12M | 49.49M | 55.72M |
| Change in Working Capital | 15.14M | (10.85M) | 2.63M | (12.03M) | 42.06M |
| Accounts Receivables | (11.72M) | 12.23M | (4.56M) | 2.97M | (1.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.25M | (17.12M) | 5.78M | 10.68M | (10.25M) |
| Other Working Capital | 10.61M | (5.95M) | 1.41M | (25.69M) | 53.72M |
| Other Non-Cash Items | 1.11M | 1.13M | 1.13M | 133K | 99K |
| Operating Cash Flow | (106.11M) | (188.19M) | (214.23M) | (375.87M) | (407.31M) |
| Capital Expenditures | (254K) | (197K) | (360K) | (759K) | (8K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (254K) | (197K) | (360K) | (759K) | (8K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 129K | 70.5M | 472.75M | 450M | 596.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 200M | 385K | (318K) | 4.49M | (504K) |
| Financing Cash Flow | 200.13M | 70.89M | 472.43M | 454.49M | 595.76M |
| Effect of Forex Changes | (92K) | 220K | 993K | 747K | (299K) |
| Net Change in Cash | 93.67M | (117.29M) | 258.83M | 78.61M | 188.14M |
| Free Cash Flow | (106.37M) | (188.39M) | (214.59M) | (376.63M) | (407.32M) |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.